Formosa Pharmaceuticals Receives the US FDA’s Approval for Clobetasol Propionate to Treat Post-Operative Inflammation and Pain Following Ocular Surgery
Shots:
- The US FDA has approved Formosa’s clobetasol propionate ophthalmic suspension 0.05% (APP13007) to treat post-operative inflammation & pain following ocular surgery
- Sosei Heptares will receive a payment of $2.5M from Formosa on achieving the milestone as per the agreement signed b/w them
- APP13007 was initially developed by Activus Pharma (subsidiary of Sosei) using its Activus Pure Nanoparticle Technology. It was divested to Formosa in Aug 2017
Ref: Globenewswire | Image: Formosa
Related News:- Formosa Entered into a License Agreement with Eyenovia to Commercialize APP13007 for Inflammation and Pain Following Ocular Surgery
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
